Stewart ColeProfessor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.
Vassily HatzimanikatisDr. Vassily Hatzimanikatis is currently Associate Professor of Chemical Engineering and Bioengineering at Ecole Polytechnique Federale de Lausanne (EPFL), in Lausanne, Switzerland. Vassily received a PhD and an MS in Chemical Engineering from the California Institute of Technology, and his Diploma in Chemical Engineering from the University of Patras, in Greece. After the completion of his doctoral studies, he held a research group leader position at the Swiss Federal Institute of Technology in Zurich (ETHZ), Switzerland. Prior to joining EPFL, Vassily worked for three years in DuPont, Cargill, and Cargill Dow, and he has been assistant professor at Northwestern University, at Illinois, USA.
Vassilys research interests are in the areas of computational systems biology, biotechnology, and complexity. He is associate editor of the journals Biotechnology & Bioengineering, Metabolic Engineering and Integrative Biology, and he serves on the editorial advisory board of the journals Bioprocess and Biosystems Engineering, Journal of Chemical Technology and Biotechnology, and Industrial Biotechnology. He has written over 70 technical publications and he is co-inventor in three patents and patent applications.
Vassily is a fellow of the American Institute for Medical and Biological Engineering (2010), he was a DuPont Young Professor (2001-2004), and he has also received the Jay Bailey Young Investigator Award in Metabolic Engineering (2000), and the ACS Elmar Gaden Award (2011).
Jacques FellayJacques Fellay is a medical scientist with expertise in infectious diseases and human genomics. He obtained his MD from the University of Lausanne in 2002 and his PhD from University of Utrecht. After a clinical training in infectious diseases in Switzerland and a 4-years postdoctoral fellowship at Duke University, he joined the EPFL in April 2011 with an SNF Professorship.
On top of his EPFL affiliation, Jacques is also Head of Precision Medicine at the University Hospital (CHUV) in Lausanne, Group Leader at the Swiss Institute of Bioinformatics, and Co-director of the Health2030 Genome Center at Campus Biotech in Geneva.
Christof HolligerOriginaire d'Adliswil, Christof Holliger est né en 1959. Diplômé de l'ETHZ en biologie en 1984, il mène des travaux de recherche dans le domaine de la microbiologie environnementale à l'Université d'Agriculture de Wageningen (Pays-Bas) où il obtient son doctorat en Science de l'environnement en 1992. En 1992, il retourne en Suisse engagé comme collaborateur scientifique et chef de groupe à l'Institut Fédéral pour l'Aménagement, l'Epuration et la Protection des Eaux (EAWAG) à Kastanienbaum. Il y continue ses recherches sur la déchloruration réductrice, commencées aux Pays-Bas, et dirige des travaux sur la réduction des composés nitroaromatiques, la réduction du fer et la méthanogenèse psychrophile dans les sédiments des lacs. En octobre 1998, il est nommé professeur assistant en biotechnologie environnementale au Département de génie rural de l'EPFL. Ses recherches visent l'application des micro-organismes anaérobies pour le traitement des eaux résiduaires. En novembre 2004, il est nommé professeur associé et devient responsable du laboratoire de biotechnologie environnementale à la Faculté de l'Environnement naturel, architectural et construit. L'utilisation des techniques de la biologie moléculaire pour la caractérisation des communautés microbiennes impliquées dans le biotraitement de l'air, des eaux et des sols pollués est un outil clé dans les différents projets de recherche visants le développement des nouveaux procédés de traitement.
Jean-Pierre HubauxJean-Pierre Hubaux is a full professor at EPFL and head of the Laboratory for Data Security. Through his research, he contributes to laying the foundations and developing the tools for protecting privacy in today’s hyper-connected world. He has pioneered the areas of privacy and security in mobile/wireless networks and in personalized health. He is the academic director of the Center for Digital Trust (C4DT). He leads the Data Protection in Personalized Health (DPPH) project funded by the ETH Council and is a co-chair of the Data Security Work Stream of the Global Alliance for Genomics and Health (GA4GH). From 2008 to 2019 he was one of the seven commissioners of the Swiss FCC. He is a Fellow of both IEEE (2008) and ACM (2010). Recent awards: two of his papers obtained distinctions at the IEEE Symposium on Security and Privacy in 2015 and 2018. He is among the most cited researchers in privacy protection and in information security. Spoken languages: French, English, German, Italian
Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Julien Maillard2011 - present: Research associate at the Laboratory for Environmental Biotechnology (LBE, IIE-ENAC, EPFL)
2007 - 2010: Postdoctoral Fellow at the Laboratory for Environmental Biotechnology (LBE, IIE-ENAC, EPFL)
2005 - 2006: Postdoctoral Fellow at the University of East Anglia (UEA, Norwich, UK)
2000 - 2004: PhD thesis at the Laboratory for Environmental Biotechnology (LBE)
1995 - 2000: B.sc & M.sc at the Swiss Federal Institute for Technology, Zurich (ETHZ)
Didier TronoAfter obtaining an M.D. from the University of Geneva and completing a clinical training in pathology, internal medicine and infectious diseases in Geneva and at Massachusetts General Hospital in Boston, Didier Trono embarked in a scientific career at the Whitehead Institute for Biomedical Research of MIT. In 1990, he joined the faculty of the Salk Institute for Biological Studies to launch a center for AIDS research. He moved back to Europe seven years later, before taking the reins of the newly created EPFL School of Life Sciences, which he directed from 2004 to 2012. He is now actively engaged in the efforts of Switzerland to integrate new technologies in the fields of precision medicine and personalized health.
